BioSpace News Archive

Worldwide Clinical Trials, the industry’s leading global, midsize, full-service contract research organization, has announced the appointment of Barry Lederman as Chief Financial Officer to lead its finance, accounting, and legal functions.

9 Meters Biopharma, Inc., a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced that the Company will participate in Citi’s 17th Annual BioPharma Conference on September 8, 2022, in Boston.

Each year, around 58,000 children ages five and younger are hospitalized due to respiratory syncytial virus, which is a very common respiratory virus.

Vaxart, Inc. announced that it has named Ray Stapleton, Ph.D., as its Chief Technology Officer, effective immediately.

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present a company update at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022 (Hybrid Conference).

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services (DSS) division has released ILDsym™ version 1A, quantitative systems pharmacology (QSP) modeling software.

iQure Pharma Inc. (iQure), a Princeton-based global biotech company, today confirmed completion of Early Closing as part of its Series A investment, which will support ongoing research into non-opioid therapeutics for neuropathic pain.

BrainsWay Ltd., a global leader in advanced and non-invasive treatment for brain disorders, announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at the H.C. Wainwright Annual Global Investment Conference being held at the Lotte Palace Hotel in New York City on September 12-14, 2022.

Alimera Sciences, Inc. announces that clinical data for ILUVIEN® 0.19mg will be featured in more than 20 scientific abstracts during the EURETINA 2022 congress being held in Hamburg, Germany from September 1-4, 2022.

Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that the Company will present and host one-on-one meetings at the H.C. Wainwright 24th Annual Global Investment Conference in September.